BioStock 2025: Veltio Pharma Highlights Innovative Solutions for Drug Development

Drug development faces many challenges, but one of the most persistent is improving the solubility of active pharmaceutical ingredients. At BioStock 2025, a key Nordic forum connecting life science companies and investors, Veltio Pharma AB presented a promising solution to this problem. The company's CEO, Stina Lundgren, shared insights on how Veltio Pharma’s algae-derived porous cellulose offers a simple and effective alternative to traditional methods.

Stina Lundgren, Veltio Pharma's CEO, presenting at BioStock 2025.

The Challenge of Solubility in Drug Development

Solubility is a critical factor in drug formulation. Many active pharmaceutical ingredients struggle to dissolve efficiently, which limits their bioavailability and therapeutic effect. This challenge often leads to increased costs and longer development times as companies search for ways to improve drug delivery.

Traditional approaches to enhance solubility include chemical modification of the drug molecule or the use of synthetic carriers. These methods can be complex, expensive, and sometimes introduce safety concerns.

Veltio Pharma’s approach focuses on a natural, sustainable material: porous cellulose derived from algae. This material acts as a carrier that improves the solubility of poorly soluble drugs without altering their chemical structure.

How Algae-Derived Porous Cellulose Works

Porous cellulose from algae has a high surface area and a unique structure that allows it to absorb and hold drug molecules effectively. This improves the dissolution rate when the drug reaches the body, enhancing its bioavailability.

Stina Lundgren explained that this material is:

• Biocompatible and safe for use in pharmaceuticals

• Sustainable, sourced from renewable algae

• Versatile, suitable for a wide range of drug molecules

  
  

This approach reduces the need for complex chemical modifications and can accelerate the drug development process.

Veltio Pharma’s Presentation at BioStock 2025

At the summit, Veltio Pharma showcased their technology and shared case studies demonstrating improved solubility for several drug candidates. The presentation highlighted how their porous cellulose can be integrated into existing drug formulations with minimal changes.

Investors and industry experts showed strong interest in the potential of this natural material to address a common bottleneck in pharmaceutical development.

Stina Lundgren presenting Veltio Pharma's drug solubility solution.

Practical Benefits for Drug Developers

Using algae-derived porous cellulose offers several practical advantages:

• Cost efficiency: Lower production costs compared to synthetic carriers

• Faster development: Simplifies formulation steps, reducing time to market

• Improved patient outcomes: Better solubility can lead to more effective drugs

• Environmental impact: Utilizes renewable resources, supporting greener pharma

  
  

These benefits make it an attractive option for pharmaceutical companies looking to improve their drug formulations without adding complexity.

Learn more about Veltio Pharma's presentation

If you want to learn more about Veltio Pharma’s approach and see the full presentation, you can visit the BioStock website here.